Chelsea Counsel Co. Sells 11,835 Shares of Sanofi $SNY

Chelsea Counsel Co. reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 86.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,910 shares of the company’s stock after selling 11,835 shares during the period. Chelsea Counsel Co.’s holdings in Sanofi were worth $93,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Flagship Harbor Advisors LLC bought a new position in Sanofi in the 4th quarter worth $25,000. Measured Wealth Private Client Group LLC bought a new stake in Sanofi during the third quarter valued at about $29,000. Palisade Asset Management LLC bought a new stake in Sanofi during the third quarter valued at about $30,000. Annis Gardner Whiting Capital Advisors LLC increased its position in Sanofi by 544.4% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in Sanofi by 48.9% in the fourth quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock worth $39,000 after buying an additional 266 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

SNY opened at $42.38 on Friday. The stock has a market capitalization of $102.75 billion, a price-to-earnings ratio of 11.84, a PEG ratio of 1.05 and a beta of 0.34. The company has a fifty day moving average of $44.79 and a 200 day moving average of $46.33. Sanofi has a fifty-two week low of $41.85 and a fifty-two week high of $52.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. This represents a dividend yield of 559.0%. Sanofi’s payout ratio is currently 49.16%.

Analysts Set New Price Targets

SNY has been the topic of a number of analyst reports. Morgan Stanley set a $52.00 price objective on Sanofi in a research report on Friday, May 1st. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research note on Monday, April 20th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Argus upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.